{"id":"NCT05075408","sponsor":"Galderma R&D","briefTitle":"To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus","officialTitle":"A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Nemolizumab in Subjects With Chronic Kidney Disease With Associated Moderate to Severe Pruritus","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2021-12-29","primaryCompletion":"2024-01-04","completion":"2024-01-04","firstPosted":"2021-10-12","resultsPosted":"2025-02-20","lastUpdate":"2025-02-20"},"enrollment":258,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Kidney Disease Associated Moderate to Severe Pruritus"],"interventions":[{"type":"DRUG","name":"Nemolizumab","otherNames":["CD14152"]},{"type":"DRUG","name":"Nemolizumab","otherNames":["CD14152"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Nemolizumab 30 mg","type":"EXPERIMENTAL"},{"label":"Nemolizumab 60 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study was to evaluate the efficacy of nemolizumab compared to placebo at reducing the intensity of pruritus after a 12-week treatment period in adult hemodialysis participants with moderate to severe pruritus.","primaryOutcome":{"measure":"Percentage of Responders With an Improvement of Worst Itch Numeric Rating Scale (WI NRS) Greater Than and Equal to (>=) 4 From Baseline at Week 12","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Nemolizumab 30 mg","deltaMin":38.5,"sd":null},{"arm":"Nemolizumab 60 mg","deltaMin":47.7,"sd":null},{"arm":"Placebo","deltaMin":32.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"0.3696"},{"comp":"OG001 vs OG002","p":"0.0686"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":64,"countries":["United States","Hungary","Poland","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":33,"n":86},"commonTop":["Hyperkalaemia","Vomiting","Diarrhoea","Anaemia","Fall"]}}